Cargando…

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

Mostrar otras versiones (1)

[Pt(O,O′-acac)(γ-acac)(DMS)] (PtAcD) is able to induce apoptosis in various human cancer cells, including the cisplatin-resistant human breast carcinoma MCF-7 cells. Here, to confirm that PtAcD has the potentiality for therapeutic intervention, we studied its effects in primary cultured epithelial b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muscella, A, Vetrugno, C, Fanizzi, F P, Manca, C, De Pascali, S A, Marsigliante, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789173/ https://www.ncbi.nlm.nih.gov/pubmed/24030148 http://dx.doi.org/10.1038/cddis.2013.315

Ejemplares similares

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells
por: Muscella, A, et al.
Publicado: (2014)

Antitumor activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in mouse xenograft model of breast cancer
por: Muscella, A, et al.
Publicado: (2014)

[Pt(O,O’-acac)(γ-acac)(DMS)] Alters SH-SY5Y Cell Migration and Invasion by the Inhibition of Na(+)/H(+) Exchanger Isoform 1 Occurring through a PKC-ε/ERK/mTOR Pathway
por: Muscella, Antonella, et al.
Publicado: (2014)

[Pt(O,O′-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells
por: Antonaci, Giovanna, et al.
Publicado: (2019)

Correction: Apoptosis by [Pt(O,O′-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma
por: Muscella, Antonella, et al.
Publicado: (2018)

Apoptosis by [Pt(O,O′-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma
por: Muscella, Antonella, et al.
Publicado: (2017)

In Vitro and In Vivo Antitumor Activity of [Pt(O,O′-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma
por: Muscella, Antonella, et al.
Publicado: (2016)

In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
por: Olszewski, Ulrike, et al.
Publicado: (2010)

Developing Central Nervous System and Vulnerability to Platinum Compounds
por: Bernocchi, G., et al.
Publicado: (2011)

Response of Cisplatin Resistant Skov-3 Cells to [Pt(O,O′-Acac)(γ-Acac)(DMS)] Treatment Revealed by a Metabolomic (1)H-NMR Study
por: De Castro, Federica, et al.
Publicado: (2018)

A NMR-Based Metabolomic Approach to Investigate the Antitumor Effects of the Novel [Pt(η(1)-C(2)H(4)OMe)(DMSO)(phen)](+) (phen = 1,10-Phenanthroline) Compound on Neuroblastoma Cancer Cells
por: De Castro, Federica, et al.
Publicado: (2022)

Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System
por: Bernocchi, Graziella, et al.
Publicado: (2015)

Synthesis and Evaluation of the Cytotoxic Activity of Water-Soluble Cationic Organometallic Complexes of the Type [Pt(η(1)-C(2)H(4)OMe)(L)(Phen)](+) (L = NH(3), DMSO; Phen = 1,10-Phenanthroline)
por: De Castro, Federica, et al.
Publicado: (2021)

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Immunolocalization of the AT-1R Ang II Receptor in Human Kidney Cancer
por: Muscella, Antonella, et al.
Publicado: (2023)

Anticancer Platinum Drugs Update
por: Ciarimboli, Giuliano
Publicado: (2021)

Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA
por: Morel, Elodie, et al.
Publicado: (2019)

Monofunctional Platinum(II) Anticancer Agents
por: Jin, Suxing, et al.
Publicado: (2021)

Evaluation of the Antitumor Effects of Platinum-Based [Pt(η(1)-C(2)H(4)-OR)(DMSO)(phen)](+) (R = Me, Et) Cationic Organometallic Complexes on Chemoresistant Pancreatic Cancer Cell Lines
por: Stefàno, Erika, et al.
Publicado: (2023)

Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties
por: Frik, Malgorzata, et al.
Publicado: (2015)

Chiral discrimination in platinum anticancer drugs.
por: Benedetti, Michele, et al.
Publicado: (2002)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

The effects of training on hormonal concentrations and physical performance of football referees
por: Muscella, Antonella, et al.
Publicado: (2021)

Computational Study of Bis-(1-(Benzoyl)-3-Methyl Thiourea) Platinum (II) Complex Derivatives as Anticancer Candidates
por: Ruswanto, Ruswanto, et al.
Publicado: (2023)

Effects on Children’s Physical and Mental Well-Being of a Physical-Activity-Based School Intervention Program: A Randomized Study
por: Marsigliante, Santo, et al.
Publicado: (2023)

Low-Intensity Light-Responsive Anticancer Activity of Platinum(II) Complex Nanocolloids on 2D and 3D In Vitro Cancer Cell Model
por: Vergaro, Viviana, et al.
Publicado: (2022)

Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
por: Jeon, Jaewan, et al.
Publicado: (2021)

The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma
por: Lu, Enzhou, et al.
Publicado: (2022)

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation
por: Wu, Bin, et al.
Publicado: (2011)

Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives
por: De Castro, Federica, et al.
Publicado: (2023)

Antiandrogen and Antimicrobial Aspects of Coordination Compounds of Palladium(II), Platinum(II) and Lead(II)
por: Singh, R. V., et al.
Publicado: (2001)

Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin
por: Barbanente, Alessandra, et al.
Publicado: (2021)

Criteria for the selection of second-generation platinum compounds.
por: Shepherd, R., et al.
Publicado: (1980)

Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity
por: Nadar, Robin A., et al.
Publicado: (2020)

Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance
por: Deng, Zhiqin, et al.
Publicado: (2023)

The Regulation of Fat Metabolism during Aerobic Exercise
por: Muscella, Antonella, et al.
Publicado: (2020)

Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents
por: Łakomska, Iwona, et al.
Publicado: (2020)

Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs
por: Qin, Zhiying, et al.
Publicado: (2020)

Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action
por: Dai, Ziwen, et al.
Publicado: (2020)

Iron(III)-Salophene: An Organometallic Compound with Selective Cytotoxic and Anti-Proliferative Properties in Platinum-Resistant Ovarian Cancer Cells
por: Lange, Thilo S., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ctmoq3q022fud5039ctu3i57qm